Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

iming and scope of clinical trials of NGX267. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of completed trials of NGX267 are predictive of results in subsequent trials of such product candidate; whether further testing of NGX267 will result in data sufficient to support regulatory approval; whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether the company will be able to develop and obtain regulatory approval of its product candidates for treatment of multiple diseases and disorders; whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its product candidates will support a filing for marketing approval, will be approved by applicable regulatory authorities, or if approved, will prove competitive in the market; and whether the necessary financing to support its product development programs will be available. Actual results may differ materially from the above forward-looking statements due to a number of other important factors. These and other risks which may impact management's expectations are described in greater detail in the TorreyPines Therapeutics ann
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
(Date:7/11/2014)... , July 11, 2014 Patient engagement ... and, consequently, organizations are turning to an assortment ... As part of this evolving approach to ... educate, communicate and engage patients throughout their experiences ... patient empowerment. By mapping the patient journey and ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the innovative ... http://www.HealthYourself101.com will expand people’s understanding of the causes, consequences, ... out to provide a health education platform on this modern ... say it? – entertaining to dig into and learn from. ... remote learner – the solitary individual signing on from a ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, Fadhits.com, a ... collection of elegant long graduation dresses to its ... promotion for its loyal clients. It wants to bring more ... items are now offered at discounted prices, up to 72% ... company is always working hard. Its online shop is a ...
(Date:7/12/2014)... The rise in the number of mobility ... network architectures to suit the upsurge. Virtualization has become ... cloud storage technologies. The data traffic has increased by ... This has resulted in larger and more complex networks. ... the SDN market. , The North American (NA) region ...
(Date:7/12/2014)... Demand Response Management Systems is a ... reducing the imbalance between energy supply and demand. With ... rolled out (due to increasing pressure on the grid) ... in controlling residential appliances and thermostats for load reduction. ... American region, and with government mandates and benefits for ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4
... 2008) -- Are you sick because you,re depressed, or are ... yes. , For more than 25 years researchers in ... showing that what you think and feel may alter your ... flip side that the immune system gone awry may ...
... patients could benefit from similar,improvements, DALLAS, ... article published today, "An organized approach to ... presented the first,head-to-head comparison of quality medical ... Disease (GWTG-CAD) hospitals vs. other US,hospitals not ...
... CITY, Calif., Sept. 8 Cardica, Inc.,(Nasdaq: CRDC ... at 11:00,a.m. Eastern Time tomorrow, September 9, to provide ... Conference Call Details, To access the live conference ... and Canada or +1-617-597-5309 internationally. The,conference ID is 57153283. ...
... 4, 2008) A new study finds hospitals can save ... patients while giving them even better care. , The ... the Center to Advance Palliative Care and National Palliative Care ... aging of the population, especially the baby boomers, hospitals are ...
... States Agency for International Development (USAID) has awarded the ... at Chapel Hill up to $181 million to continue ... largest ever received by UNC. , The award funds ... child health, nutrition and HIV/AIDS programs around the world. ...
... blunted in people with above-average activity scores, study finds , , ... the risk of obesity in people with a genetic mutation ... U.S. study. , Recent research has shown a link ... associated with the (FTO) gene. The mutations connected with ...
Cached Medicine News:Health News:Nation's top experts in psychoneuroimmunology to gather Sept 18-21 in Tampa, Fla. 2Health News:Nation's top experts in psychoneuroimmunology to gather Sept 18-21 in Tampa, Fla. 3Health News:Nation's top experts in psychoneuroimmunology to gather Sept 18-21 in Tampa, Fla. 4Health News:Hospitals Participating in Get With The Guidelines(SM) Program Follow Heart Attack Treatment Guidelines Better Than Others 2Health News:Cardica to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Provide Positive Update on Pas-Port(R) 2Health News:Better care of sickest patients can actually save hospitals money, says largest study of its kind 2Health News:UNC receives record $181 million grant to evaluate health, poverty and gender programs worldwide 2Health News:Vigorous Exercise Aids Those With Obesity-Related Gene 2
... simplified focusing guidance system has ... to use of its type. Technicians ... LM-770 with a minimum of instruction. ... target lines to focus first. A ...
... is the newest generation of electronic refractors. The ... control the refractor from a keypad that is small ... controls the CP-670 Automatic Chart Projector. The TRS is ... all the lenses are moved for you, taking you ...
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
The Manual Table Base is elevated with an easy to reach elevating wheel for smooth operation. The table base will accept a slit lamp, a single table top, or a double tabletop for more than one instru...
Medicine Products: